

November 7, 2022



# Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022

## Company to host a Conference Call & Webcast at 8:00 a.m. ET

CHESTERBROOK, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- **Trevena, Inc. (Nasdaq: TRVN)**, a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2022, prior to the market open on Wednesday, November 9, 2022.

The Company will host a conference call and webcast with the investment community at 8:00 a.m. ET that same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Patricia Drake, SVP and Chief Commercial Officer, Mark Demitrack, M.D., SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Officer.

**Title:** Trevena Third Quarter 2022 Financial Results  
Conference Call & Webcast

**Date:** Wednesday, November 9, 2022

**Time:** 8:00 a.m. ET

**Conference Call Details:** Toll-Free: 1-800-954-0687  
International: 1-212-231-2935  
Conference ID: 22021290

The conference call will be webcast live from the Company's website and will be available via the following links:

**Webcast:** [https://viaid.webcasts.com/starthere.jsp?ei=1572499&tp\\_key=b8766e3409](https://viaid.webcasts.com/starthere.jsp?ei=1572499&tp_key=b8766e3409)

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company's website.

### About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK<sup>®</sup> (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid

analgesic and for whom alternative treatments are inadequate. The Company's novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder.

For more information, please visit [www.Trevena.com](http://www.Trevena.com)

**For more information, please contact:**

**Investor Contact:**

Dan Ferry - Managing Director  
LifeSci Advisors, LLC  
[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)  
(617) 430-7576

**PR & Media Contact:**

Sasha Bennett  
Associate Vice President  
Clyde Group  
[Sasha.Bennett@clydegroupp.com](mailto:Sasha.Bennett@clydegroupp.com)  
(239) 248-3409

**Company Contact:**

Bob Yoder  
SVP and Chief Business Officer  
Trevena, Inc.  
(610) 354-8840



Source: Trevena, Inc.